CPRX Q1 2023 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$85M+98.1% YoY

Gross Profit

$75M88.3% margin

Operating Income

$36M41.7% margin

Net Income

$30M34.6% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

+40.5%

Cash Flow

Operating Cash Flow

$12M

Free Cash Flow

-$150M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$407M

Total Liabilities

$74M

Stockholders' Equity

$334M

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$85M	$43M	+98.1%
Gross Profit	$75M	$37M	+102.7%
Operating Income	$36M	$17M	+105.1%
Net Income	$30M	$13M	+123.3%

Revenue Segments

Product Revenue Net

$85M100%

License And Other Revenue

$62,0000%